Reply: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.
作者信息
Celsa Ciro, Cabibbo Giuseppe, Pinato David J
机构信息
Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK.
Gastroenterology and Hepatology Unit, Department of Health Promotion, Mother & Child Care, Internal Medicine & Medical Specialties, University of Palermo, Palermo, Italy.
出版信息
Hepatology. 2025 Mar 1;81(3):E103-E104. doi: 10.1097/HEP.0000000000001217. Epub 2024 Dec 25.
PMID:39724005
Abstract
摘要
Zotero 插件